Recent News


EnterpriseWorks startup, Aptimmune Biologics, was recently recognized as one of seven Ag Tech start-ups to watch in 2018 by 

Aptimmune focuses on developing revolutionary swine vaccines and the prevention of the diseases, porcine reprodutive, respiratory syndrome virus ({PRRSV), and influenza. 

In November, Aptimmune launched the industry's first inactivated mucosal influenza A virus vaccine in swine. 

Recently, the company raised $6 Million Series B Funding from various investors and has moved its headquarters to St. Louis. 

AptImmune Photo

Aptimmune Biologics Inc. recently launched the worlds first commercially available mucosal autogenous PRRSV vaccine for swine, administered via nasal spray. The vaccine was made with BARRICADE formulation technology, which offers a revolutionary approach to PRRSV management. 


CHAMPAIGN -- Aptimmune Biologics was selected by The Yield Lab, a St. Louis-based agriculture technology business accelerator and investor, to participate in a nine-month program designed to support emerging ag tech companies. Aptimmune Biologics was chosen from among 120 applicants to participate in the program for 2016 and represents The Yield Labs first animal health investment.


Company will create new swine vaccines based on advanced mucosal technology   

New CEO joins the company to drive development and commercialization

CHAMPAIGN, Illinois – July 9, 2015 – Aptimmune Biologics, a mucosal vaccine company developing novel swine vaccines for PRRSV and influenza virus, has received $2.75 million of funding from Arsenal Capital Management, Fox Ventures LLC, and a group of Midwest angel investors.